Answers are grounded in this paper and cite their sources.
Retrospective analysis uncovers rare RAS and RAF co-mutations in colorectal cancer, suggesting implications for therapy.
e15581 Background: In colorectal cancer (CRC), mutations in RAS family genes and BRAF are typically mutually exclusive. However, with the widespread application of next-generation sequencing (NGS), case reports of such co-mutations are accumulating, warranting a systematic investigation of their genomic features, cooperative mechanisms, and clinical significance. Methods: A retrospective analysis was performed on a CRC patient cohort who underwent DNA-based NGS using a 733-gene panel (full-length coverage) between 2023 and 2025. Samples were primarily formalin-fixed, paraffin-embedded (FFPE) tissues, mostly from primary sites. Results: Among 1379 CRC patients, 834 harbored RAS and/or RAF mutations. Seventeen patients (1.23%, 17/1379) exhibited concurrent RAS and RAF mutations. The co-mutation patterns were: KRAS+BRAF in 13 patients (76.47%), NRAS+BRAF in 3 (17.65%), and KRAS+ARAF in 1 (5.88%). The cohort included 11 males (64.71%) with a median age of 61 years (range: 49-88), and 15 cases (88.24%) originated in the colon. KRAS variant sites included G12C/D/V (n = 6), A146T/V (n = 4), G13C/A59S/Q61H/K147E (each n = 1). NRAS variants included G12C/D (n = 2) and Q61L (n = 1). These RAS mutations clustered in critical functional domains (exons 2-4), disrupting the P-loop, Switch II region, and G-domain, thereby abrogating guanosine triphosphatase (GTPase) activity and causing constitutive activation. BRAF mutations comprised: Class I V600E (n = 5); Class II G469A/R (n = 2) and K601N (n = 3); Class III D594E/N (n = 3) and G466E (n = 1); and unclassified variants F247L and F468S (each n = 1). These mutations predominantly localized to the kinase domain (exons 11/15), affecting key functional regions including the P-loop, A-loop. The co-occurrence of RAS and BRAF may lead to additive MAPK pathway activation, with cooperative mechanisms varying by BRAF mutation class: (1) RAS + Class III BRAF (low kinase activity): RAS activation provides sustained upstream signaling, potentially maintaining moderate but persistent pathway output. (2) RAS + Class II BRAF (moderate kinase activity, RAS-independent): Co-mutation may amplify signaling via positive feedback or enhanced dimerization. (3) RAS + Class I BRAF V600E (high kinase activity): Both are strong activators; this rare combination might lead to excessive signaling, possibly subject to negative selection during tumor evolution. Conclusions: Co-mutations in RAS and RAF represent a rare but noteworthy genomic event in CRC. They likely confer resistance to single-agent targeted therapies, such as EGFR monoclonal antibodies and BRAF inhibitors. Future therapeutic strategies should consider multi-level MAPK pathway inhibition (combining MEK inhibitors or RAF dimer inhibitors). The precise biological functions and clinical prognosis associated with these co-mutations require further validation with treatment response and survival data.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: